Is adiponectin a risk factor for transient ischaemic attacks?

Endokrynologia Polska

Volumn 66, Issue 3, 2015, Pages 214-218

  Sener, Ufuk ^a   Uludag, Irem Fatma ^a   Kose, Sukran ^a   Ozcelik, Murat ^a   Zorlu, Yasar ^a  

^a MH Tepecik Research and Training Hospital   (Turkey)

Author keywords

Adiponectin; Atherosclerosis; Intima media thickness; Lipid profile; Transient ischaemic attack

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN; ADIPOQ PROTEIN, HUMAN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BRAIN ISCHEMIA; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; WAIST HIP RATIO; AGED; BLOOD; METABOLISM; MIDDLE AGED;

ADIPONECTIN; AGED; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84937961925     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2015.0027     Document Type: Article

References (31)

1. Lindberg S, Mogelvang R, Pedersen SH et al. Relation of serum adiponectin levels to number of traditional atherosclerotic risk factors and all-cause mortality and major adverse cardiovascular events (from the Copenhagen City Heart Study). Am J Cardiol 2013; 15: 1139-1145.
2. Nishimura M, Izumiya Y, Higuchi A et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase-dependent mechanisms. Circulation 2008; 117: 216-223.
3. Kim BJ, Lee S, Ryu W et al. Adipocytokines and ischemic stroke: differential associations between stroke subtypes. J Neurol Sci 2012; 312: 117-122.
4. Soderberg S, Stegmayr B, Stenlund H et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med 2004; 256: 128-36.
5. http://whqlibdoc.who.int/publications/2011/9789241501491-eng.pdf.
6. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001440.
7. Iglseder B, Mackevics V, Stadlmayer A et al. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR study. Stroke 2005; 36: 2577-2582.
8. Tahmasebpour HR, Buckley AR, Cooperberg PL et a. Sonographic examination of the 9 carotid arteries. Radiographics 2005; 25: 1561-1575.
9. Chen M, Tsai JC, Chung F et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 821-826.
10. Stott DJ, Welsh P, Rumley A et al. Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol 2009; 38: 253-261.
11. Jaleel A, Agil S, Jaleel F et al. Adiponectin and infarction size in subjects with and without cerebrovascular disease. Neurosciences (Riyadh) 2009; 14: 245-248.
12. Kantorova E, Chomova M, Kurca E et al. Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke. Neuro Endocrinol Lett 2011; 32: 716-721.
13. Jaleel A, Aqil S, Jaleel S et al. Adipocytokines in subjects with and without ischemic cerebrovascular disease. Acta Neurol Belg 2010; 110: 234-238.
14. Baranowska B, Kochanowski J, Grudniak M et al. Decreased total serum adiponectin and its isoforms in women with acute ischemic stroke. Neuro Endocrinol Lett 2011; 32: 711-715.
15. Marousi S, Theodorou G, Karakantza M et al. Serum adiponectin acutely after an ischemic stroke: implications for a long-lasting, supressed anti-inflammatory role. Acta Neurol Scand 2010; 121: 277-284.
16. Prugger C, Luc G, Haas B et al. on behalf of the PRIME study group. Ann Neurol 2012; 71: 478-486.
17. Prugger C, Luc G, Hass B et al. on behalf of the PRIME study group. Multiple biomarkers for the prediction of ischemic stroke the PRIME study. Arterioscler Thromb Vasc Biol 2013; 33: 659-666.
18. Matsumoto M, Ishikawa S, Kajii E. Association of adiponectin with cerebrovascular disease. A nested case-control study. Stroke 2008; 39: 323-328.
19. Ogorodnikova AD, Wassertheil-Smoller S, Mancuso P et al. High- molecular-weight adiponectin and incident ischemic stroke in postmenopausal women. A women's health initiative study. Stroke 2010; 41: 1376-1381.
20. Bienek R, Marek B, Kajdaniuk D et al. Adiponectin, leptin, resistin and insulin blood concentrations in patients with ischaemic cerebral stroke. Endokrynol Pol 2012; 63: 338-345.
21. Rajpathak SN, Kaplan RC, Wassertheil-Smoller S et al. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: results from the women's health initiative. Stroke 2011; 42: 1813-1820.
22. Wannamethee SG, Shaper AG, Whincup PH et al. Adiposity, adipokines, and risk of incident stroke in older men. Stroke 2013; 44: 3-8.
23. Kanhai DA, Kranendonk ME, Uiterwaal CSPM et al. Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes Rev 2013; 14: 555-567.
24. Hao G, Li W, Guo R et al. Serum total adiponectin level and the risk of cardiovascular disease in general population: A meta-analysis of 17 prospective studies. Atherosclerosis 2013; 228: 29-35.
25. Nagasawa H, Yokota C, Toyoda K et al. High level of plasma adiponectin in acute stroke patients is associated with stroke mortality. J Neurol Sci 2011; 304: 102-106.
26. Marousi SG, Theodorou GL, Karakantza M et al. Acute post-stroke adiponectin in relation to stroke severity, progression and 6 month functional outcome. Neurol Res 2010; 32: 841-844.
27. Bevan S, Meidtner K, Lorenz M et al. Adiponectin level as a consequence of genetic variation, but not leptin level or leptin. Adiponectin ratio, is a risk factor for carotid intima-media thickness. Stroke 2011; 42: 1510-1514.
28. Persson J, Folkersen L, Ekstrand J et al. High plasma adiponectin concentration is associated with all-cause mortality in patients with carotid atherosclerosis. Atherosclerosis 2012; 225: 491-496.
29. Gardener H, Sjoberg C, Crisby M et al. Adiponectin and carotid intima- media thickness in the Northern Manhattan study. Stroke 2012; 43: 1123-1125.
30. Afzal S, Sattar MA, Rathore HA et al. Adiponectin versus thiazolidinediones and angiotensin receptor blockers. ESJ 2013; 9; 100-129.
31. Perelas A, Tsoulkani A, Perrea D. Effects of lipid-lowering drugs on adiponectin. Curr Vasc Pharmacol 2010; 8: 836-848.